Turing Venture Capital invests $50,000 in Molarity’s pre-seed round

Molarity’s tagline carries the product thesis in one line: know the market before you sign the lease. In the company’s own words, the product “brings local demand, competition, economics, referral patterns, and pay into one clear view for any US address.” Molarity states that its inputs are entirely public: a national provider registry, live business listings, US Census data, and state fee schedules. The output is one drive-time boundary per market, benchmarked against national figures, specialty by specialty.

The coverage claims are specific enough to be checked. That is why they are worth underwriting. The company reports 85,000 census tracts weighted to the exact shape of a market, seven specialty lenses, and live coverage across all 50 states, with every drive-time boundary clipped at real water so nobody counts patients in the bay. The seven lenses that have shipped are all dental: general dentistry, orthodontics, pediatric dentistry, periodontics, oral surgery, endodontics, and prosthodontics.

The commercial model matches the product rather than the fundraising fashion. Anyone can explore three sites a day for free, with no card and no sign-in. A Pro Deep Report is $475 once, for a single market: named competitor directory, referral outreach lists, the fee spectrum, written analysis, and PDF export. Two reports are $675. A Market Refresh, which reruns the analysis on current data, is $50. The company states the position plainly: “No subscriptions. No seat licenses. You pay only for the data that costs money to produce.”

Turing organizes its portfolio by thesis pillar rather than by sector or stage, because the pillar tells you why a company was backed. Molarity maps to Pillar 01, The Architect Economy, which holds that value accrues to those who build the substrate, not those who decorate it. That pillar names proprietary data systems first among the substrates worth owning, and it names what Turing passes on: a horizontal product any well-funded competitor could rebuild in a quarter. We are underwriting the assembly beneath the interface, on the bet that coverage of this kind compounds faster than it can be rebuilt.

The secondary fit is Pillar 02, vertical depth over horizontal generality. This is not analysis for everyone. The examples are general dentists and orthodontists, and the fee spectrum runs from a state Medicaid floor to a modeled private-pay median, which the company labels an estimate and never a quote, on a named procedure in a named state. The restraint is written into the product: benchmarks, never verdicts, with the decision left to the practitioner. Domain specificity of that kind is slow to build and slow to copy.

The counter-case: every input here is public. A national provider registry, the Census, and 51 state fee schedules are available to anyone willing to pull them, and an analysis layer is not by itself a moat. There is no published customer count and no revenue figure, and we are not going to invent one. The bet is narrow. Assembly is harder than access, and re-verifying fee schedules and clipping boundaries at real water is unglamorous enough that most competitors will not sustain it. If that is wrong, we would rather be wrong at $50,000.

The check is $50,000, which sits below Turing’s published first-check band of $100K to $500K. That is a judgment about stage, not a hedge on the company. A $50,000 check does not change a company’s trajectory. It buys a position next to people doing slow, unglamorous assembly work in a market that pays for it late. We are comfortable waiting.